Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 7/20 | 0.35 |
| ▸ | AXL | P30530 | 6/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29814251 | 0.89 | CA12 (0.37) | METAXL | |
| SCHEMBL23071244 | 0.83 | LMNA (0.44) | KDM4ELMNAMETAXL | |
| SCHEMBL14968894 | 0.83 | NOTUM (0.47) | KDM4ELMNANOTUMMETAXL | |
| SCHEMBL14969073 | 0.82 | KDM4E (0.46) | KDM4ELMNANOTUML3MBTL1MET | |
| SCHEMBL22511419 | 0.82 | MET (0.47) | KDM4ELMNANOTUML3MBTL1MET | |
| SCHEMBL14969174 | 0.82 | KDM4E (0.43) | KDM4ELMNANOTUML3MBTL1MET | |
| SCHEMBL14967274 | 0.81 | MET (0.46) | KDM4ELMNANOTUML3MBTL1MET | |
| SCHEMBL14966728 | 0.80 | MET (0.47) | KDM4ELMNANOTUML3MBTL1MET | |
| SCHEMBL14969151 | 0.80 | MET (0.46) | KDM4ELMNANOTUML3MBTL1MET | |
| SCHEMBL14969007 | 0.80 | MET (0.47) | KDM4ELMNANOTUML3MBTL1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | claimed |
| CN-116283916-B | Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof | 中国科学院上海药物研究所 | 2024-06-11 | — | — | CN | disclosed |
| CN-116283916-A | Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof | 中国科学院上海药物研究所 | 2023-06-23 | — | — | CN | disclosed |
| CN-112457295-B | Compound with Axl and c-Met kinase inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2022-07-26 | — | — | CN | disclosed |
| EP-4029862-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021043217-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-03-11 | — | — | WO | disclosed |
| WO-2021043217-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-03-11 | — | — | WO | disclosed |
| CN-112457295-A | Compound with Axl and c-Met kinase inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2021-03-09 | — | — | CN | disclosed |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| CN-108047201-A | Uracil derivative as AXL and c-MET kinase inhibitors | 亚尼塔公司 | 2018-05-18 | — | — | CN | disclosed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-3045453-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9120778-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2780338-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | Cephalon, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2013074633-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | KDM4E 1352/4885LMNA 3405/4885NOTUM 4849/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | KDM4E 1352/4885LMNA 3405/4885NOTUM 4849/4885 |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | AXL, RET, FLT3 | KDM4E 1213/4885LMNA 3883/4885NOTUM 4830/4885 |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | KDM4E 1352/4885LMNA 3405/4885NOTUM 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.